Macular Cystoid Edema Induced by Nab-Paclitaxel
Gespeichert in:
| Titel: | Macular Cystoid Edema Induced by Nab-Paclitaxel |
|---|---|
| Autoren: | Jorge E. Moreira, Carolina Vale, Filipa Sampaio, Sara Pereira |
| Quelle: | Acta Médica Portuguesa, Vol 35, Iss 4 (2022) |
| Verlagsinformationen: | Ordem dos Medicos, 2022. |
| Publikationsjahr: | 2022 |
| Schlagwörter: | Male, Albumins/adverse effects, Medicine (General), Paclitaxel, Adenocarcinoma, Middle Aged, Antineoplastic Agents, Phytogenic, Pancreatic Neoplasms, 03 medical and health sciences, R5-920, 0302 clinical medicine, Albumin-Bound Paclitaxel/adverse effects, Pancreatic Neoplasms/drug therapy, Albumins, Macular Edema/chemically induced, Paclitaxel/adverse effects, Medicine, Edema, Humans |
| Beschreibung: | A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively. The optical coherence tomography revealed bilateral severe macular edema. Macular edema was considered secondary to nab-paclitaxel and the drug was discontinued. Three months after drug discontinuation, the patient presented best corrected visual acuities of 20/20 and 16/20 in the right and left eye, respectively, and normal fundoscopy. Macular edema is a very rare side effect of taxanes, and the etiopathology is still unknown. Edema is usually reversible upon discontinuation of the offending agent. Clinicians should be aware of this adverse effect of taxanes, and a high index of clinical suspicion is essential for diagnosis. |
| Publikationsart: | Article |
| ISSN: | 1646-0758 0870-399X |
| DOI: | 10.20344/amp.13421 |
| Zugangs-URL: | https://actamedicaportuguesa.com/revista/index.php/amp/article/download/13421/6399 https://pubmed.ncbi.nlm.nih.gov/34287143 https://doaj.org/article/f77993dfe5ed40c28d941d8ae626193c https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/download/13421/6399 https://www.ncbi.nlm.nih.gov/pubmed/34287143 |
| Rights: | CC BY NC ND |
| Dokumentencode: | edsair.doi.dedup.....14b4fb9a2aaed9d5dde3b356b64d61d8 |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively. The optical coherence tomography revealed bilateral severe macular edema. Macular edema was considered secondary to nab-paclitaxel and the drug was discontinued. Three months after drug discontinuation, the patient presented best corrected visual acuities of 20/20 and 16/20 in the right and left eye, respectively, and normal fundoscopy. Macular edema is a very rare side effect of taxanes, and the etiopathology is still unknown. Edema is usually reversible upon discontinuation of the offending agent. Clinicians should be aware of this adverse effect of taxanes, and a high index of clinical suspicion is essential for diagnosis. |
|---|---|
| ISSN: | 16460758 0870399X |
| DOI: | 10.20344/amp.13421 |